Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEMA Buprenorphine long-term safety in chronic low back pain
NCT01431742Phase 3Withdrawn
- Sponsor
- BioDelivery Sciences International
- Start
- Jul 2012
- Primary completion
- Jul 2013
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of buprenorphine in chronic low back pain (CLBP), sponsored by BioDelivery Sciences International. Primary endpoint: Mean change in pain intensity at Week 52. Planned start Jul 2012; status: withdrawn.
02
Drugs
buprenorphine
03
Conditions
chronic low back pain (CLBP)
Beyond the preview
Go deeper on NCT01431742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01431742.